Clinical efficacy of anakinra to mitigate CAR T-cell therapy-associated toxicity in large B-cell lymphoma.
作者信息
Strati Paolo, Ahmed Sairah, Kebriaei Partow, Nastoupil Loretta J, Claussen Catherine M, Watson Grace, Horowitz Sandra B, Brown Anne Rain T, Do Bryan, Rodriguez Maria A, Nair Ranjit, Shpall Elizabeth J, Green Michael R, Neelapu Sattva S, Westin Jason R
机构信息
Department of Lymphoma and Myeloma.
Department of Stem Cell Transplantation and Cellular Therapy.
出版信息
Blood Adv. 2020 Jul 14;4(13):3123-3127. doi: 10.1182/bloodadvances.2020002328.
Abstract
摘要
相似文献
1
Clinical efficacy of anakinra to mitigate CAR T-cell therapy-associated toxicity in large B-cell lymphoma.阿那白滞素减轻大B细胞淋巴瘤中CAR T细胞治疗相关毒性的临床疗效。
Blood Adv. 2020 Jul 14;4(13):3123-3127. doi: 10.1182/bloodadvances.2020002328.
2
Efficacy and toxicity for CD22/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma involving the gastrointestinal tract.CD22/CD19 嵌合抗原受体 T 细胞疗法治疗累及胃肠道的复发/难治性侵袭性 B 细胞淋巴瘤患者的疗效和毒性。
Cytotherapy. 2020 Mar;22(3):166-171. doi: 10.1016/j.jcyt.2020.01.008. Epub 2020 Feb 13.
3
Chimeric antigen receptor T-cell therapy for the treatment of aggressive B-cell non-Hodgkin lymphomas: efficacy, toxicity, and comparative chimeric antigen receptor products.嵌合抗原受体 T 细胞疗法治疗侵袭性 B 细胞非霍奇金淋巴瘤：疗效、毒性和比较嵌合抗原受体产品。
Expert Opin Biol Ther. 2019 Nov;19(11):1157-1164. doi: 10.1080/14712598.2019.1644316. Epub 2019 Jul 25.
4
Chimeric antigen receptor modified T cell therapy in B cell non-Hodgkin lymphomas.嵌合抗原受体修饰 T 细胞疗法治疗 B 细胞非霍奇金淋巴瘤。
Am J Hematol. 2019 May;94(S1):S18-S23. doi: 10.1002/ajh.25403. Epub 2019 Jan 24.
5
Ibrutinib improves the efficacy of anti-CD19-CAR T-cell therapy in patients with refractory non-Hodgkin lymphoma.依鲁替尼可提高难治性非霍奇金淋巴瘤患者抗 CD19-CAR T 细胞疗法的疗效。
Cancer Sci. 2021 Jul;112(7):2642-2651. doi: 10.1111/cas.14915. Epub 2021 May 10.
6
Updates on CAR T-cell therapy in B-cell malignancies.嵌合抗原受体 T 细胞疗法治疗 B 细胞恶性肿瘤的最新进展。
Immunol Rev. 2019 Jul;290(1):39-59. doi: 10.1111/imr.12774.
7
Third-generation anti-CD19 chimeric antigen receptor T-cells incorporating a TLR2 domain for relapsed or refractory B-cell lymphoma: a phase I clinical trial protocol (ENABLE).三代抗 CD19 嵌合抗原受体 T 细胞融合 TLR2 结构域治疗复发或难治性 B 细胞淋巴瘤：一项 I 期临床试验方案（ENABLE）。
BMJ Open. 2020 Feb 9;10(2):e034629. doi: 10.1136/bmjopen-2019-034629.
8
Chimeric Antigen Receptor-Engineered T Cell Therapy in Lymphoma.嵌合抗原受体修饰 T 细胞治疗淋巴瘤。
Curr Oncol Rep. 2019 Mar 27;21(5):38. doi: 10.1007/s11912-019-0789-z.
9
Anti-CD19 CAR T-Cell Therapy for B-Cell Non-Hodgkin Lymphoma.抗 CD19 CAR T 细胞疗法治疗 B 细胞非霍奇金淋巴瘤。
Transfus Med Rev. 2020 Jan;34(1):29-33. doi: 10.1016/j.tmrv.2019.08.003. Epub 2019 Aug 29.
10
Anakinra utilization in refractory pediatric CAR T-cell associated toxicities.阿那白滞素在难治性儿童嵌合抗原受体T细胞相关毒性中的应用。
Blood Adv. 2022 Jun 14;6(11):3398-3403. doi: 10.1182/bloodadvances.2022006983.
引用本文的文献
1
Cytokine release syndrome in solid tumors.实体瘤中的细胞因子释放综合征
Cancer. 2025 Sep 1;131(17):e70069. doi: 10.1002/cncr.70069.
2
The CXCL16/CXCR6 axis is linked to immune effector cell-associated neurotoxicity in chimeric antigen receptor (CAR) T cell therapy.在嵌合抗原受体（CAR）T细胞疗法中，CXCL16/CXCR6轴与免疫效应细胞相关的神经毒性有关。
Genome Med. 2025 Jun 30;17(1):71. doi: 10.1186/s13073-025-01498-6.
3
Neurological complications of CAR T cell therapy for cancers.嵌合抗原受体（CAR）T细胞疗法治疗癌症的神经并发症
Nat Rev Neurol. 2025 Jun 25. doi: 10.1038/s41582-025-01112-8.
4
Management strategies for CAR-T cell therapy-related toxicities: results from a survey in Greece.嵌合抗原受体T细胞（CAR-T）疗法相关毒性的管理策略：希腊一项调查的结果
Front Med (Lausanne). 2025 May 30;12:1553966. doi: 10.3389/fmed.2025.1553966. eCollection 2025.
5
Intrinsic immunosuppressive features of monocytes suppress CAR-T19 through IL-1 pathway modulation in mantle cell lymphoma.单核细胞的内在免疫抑制特性通过调节白细胞介素-1途径抑制套细胞淋巴瘤中的CAR-T19。
Mol Ther Oncol. 2025 Apr 19;33(2):200985. doi: 10.1016/j.omton.2025.200985. eCollection 2025 Jun 18.
6
Chimeric antigen receptor T cell immunotherapy‑associated hemophagocytic lymphohistiocytosis: Pathogenesis, clinical manifestation, diagnosis and management compared with cytokine release syndrome (Review).嵌合抗原受体T细胞免疫疗法相关噬血细胞性淋巴组织细胞增生症：与细胞因子释放综合征相比的发病机制、临床表现、诊断及管理（综述）
Mol Med Rep. 2025 Aug;32(2). doi: 10.3892/mmr.2025.13578. Epub 2025 May 26.
7
Immunotherapy-related cognitive impairment after CAR T cell therapy in mice.小鼠接受嵌合抗原受体T细胞疗法后与免疫疗法相关的认知障碍
Cell. 2025 May 7. doi: 10.1016/j.cell.2025.03.041.
8
Deep insight into cytokine storm: from pathogenesis to treatment.深入洞察细胞因子风暴：从发病机制到治疗。
Signal Transduct Target Ther. 2025 Apr 16;10(1):112. doi: 10.1038/s41392-025-02178-y.
9
Novel strategies to manage CAR-T cell toxicity.管理嵌合抗原受体T细胞毒性的新策略。
Nat Rev Drug Discov. 2025 May;24(5):379-397. doi: 10.1038/s41573-024-01100-5. Epub 2025 Feb 3.
10
Management of chimeric antigen receptor T-cell-related toxicity of a patient affected by cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome, followed by an intestinal perforation: a case report.细胞因子释放综合征和免疫效应细胞相关神经毒性综合征患者的嵌合抗原受体T细胞相关毒性管理，随后发生肠穿孔：一例报告
J Med Case Rep. 2025 Jan 20;19(1):27. doi: 10.1186/s13256-024-04905-5.
本文引用的文献
1
Silencing the cytokine storm: the use of intravenous anakinra in haemophagocytic lymphohistiocytosis or macrophage activation syndrome.抑制细胞因子风暴：静脉注射阿那白滞素在噬血细胞性淋巴组织细胞增生症或巨噬细胞活化综合征中的应用
Lancet Rheumatol. 2020 Jun;2(6):e358-e367. doi: 10.1016/S2665-9913(20)30096-5. Epub 2020 May 4.
2
CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial.CD4/CD8 T 细胞选择影响嵌合抗原受体（CAR）T 细胞效力和毒性：一项抗 CD22 CAR T 细胞试验的 I 期更新结果。
J Clin Oncol. 2020 Jun 10;38(17):1938-1950. doi: 10.1200/JCO.19.03279. Epub 2020 Apr 14.
3
Self-Reported Incident Hypertension and Long-Term Kidney Function in Living Kidney Donors Compared with Healthy Nondonors.自述的高血压事件与活体肾供者和健康非供者的长期肾功能比较。
Clin J Am Soc Nephrol. 2019 Oct 7;14(10):1493-1499. doi: 10.2215/CJN.04020419. Epub 2019 Sep 19.
4
Hitting a Moving Target: Successful Management of Diffuse Large B-cell Lymphoma Involving the Mesentery With Volumetric Image-guided Intensity Modulated Radiation Therapy.击中移动目标：采用容积图像引导调强放射治疗成功治疗累及肠系膜的弥漫性大 B 细胞淋巴瘤。
Clin Lymphoma Myeloma Leuk. 2019 Jan;19(1):e51-e61. doi: 10.1016/j.clml.2018.09.002. Epub 2018 Sep 10.
5
Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells.单核细胞衍生的白细胞介素-1 和白细胞介素-6 对于 CAR T 细胞引起的细胞因子释放综合征和神经毒性是有差异需求的。
Nat Med. 2018 Jun;24(6):739-748. doi: 10.1038/s41591-018-0036-4. Epub 2018 May 28.
6
CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade.嵌合抗原受体 T 细胞引起的细胞因子释放综合征是由巨噬细胞介导的，并可通过白细胞介素-1 阻断来减轻。
Nat Med. 2018 Jun;24(6):731-738. doi: 10.1038/s41591-018-0041-7. Epub 2018 May 28.
7
Chimeric antigen receptor T-cell therapy - assessment and management of toxicities.嵌合抗原受体 T 细胞疗法 - 毒性的评估和管理。
Nat Rev Clin Oncol. 2018 Jan;15(1):47-62. doi: 10.1038/nrclinonc.2017.148. Epub 2017 Sep 19.
8
Interleukin-1 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation Syndrome: Reanalysis of a Prior Phase III Trial.白细胞介素-1受体阻断与具有巨噬细胞活化综合征特征的脓毒症患者死亡率降低相关：对一项既往III期试验的重新分析
Crit Care Med. 2016 Feb;44(2):275-81. doi: 10.1097/CCM.0000000000001402.
9
Therapeutic role of anakinra, an interleukin-1 receptor antagonist, in the management of secondary hemophagocytic lymphohistiocytosis/sepsis/multiple organ dysfunction/macrophage activating syndrome in critically ill children*.阿那白滞素（一种白细胞介素-1受体拮抗剂）在危重症儿童继发性噬血细胞性淋巴组织细胞增生症/脓毒症/多器官功能障碍/巨噬细胞活化综合征治疗中的作用*
Pediatr Crit Care Med. 2014 Jun;15(5):401-8. doi: 10.1097/PCC.0000000000000078.
10
Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition.对白细胞介素-1β抑制有反应的新生儿期起病的多系统炎性疾病
N Engl J Med. 2006 Aug 10;355(6):581-92. doi: 10.1056/NEJMoa055137.
Zotero 插件